Clinical Trials · NCT05669664
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- National Cancer Institute (NCI)
- Enrollment
- 21
- Start date
- Jul 2023
- Locations
- 27 sites, United States
- Primary endpoint
- Best overall response (BOR)